Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor
Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…Treatment Patterns in Essential Tremor: Real-World Evidence from Germany
Objective: To investigate the treatment patterns (TP), healthcare resource utilization (HCRU), and costs of essential tremor (ET) in a real-world setting in Germany using insurance…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers
Objective: A survey of neurology Advanced Practice Providers (APPs) provides insights into their perspectives on managing and treating patients with Parkinson’s disease (PD) in the…Placebo response in Parkinson’s disease (PD) is predicted by expression levels of a specific brain network
Objective: To determine whether baseline expression levels for the previously validated sham surgery-related metabolic pattern (SSRP) can be used to predict the magnitude of the…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Real-World Utilization of Istradefylline Among Patients with Parkinson’s Disease
Objective: This study examined real-world utilization of istradefylline and other PD-related medications before and after istradefylline initiation. Background: Istradefylline is indicated as adjunctive therapy to…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 34
- Next Page »